RxDoctor Payments DataLook up a doctor →

Christina Chu, MD

Gynecologic Oncology · Camden, NJNPI 1063444180

Payments from drug & device makers

$1,006,418in general payments, 2019–2025

Across 334 payments — averaging $3013.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$483K
  • Deciphera Pharmaceuticals Inc.$293K
  • Tesaro, Inc.$180K
  • Seagen Inc.$32K
  • Genmab U.S., Inc.$16K
  • Merck$2K
  • plus $53 from 2 others

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK69$482,527
Deciphera Pharmaceuticals Inc.226$293,433
Tesaro, Inc.9$179,948
Seagen Inc.14$31,757
Genmab U.S., Inc.9$16,360
Merck5$2,339
Clovis Oncology, Inc.1$39
CSL Behring1$14

How this compares

$1,006,418 in reported general payments places this provider in the 90th percentile of 45 gynecologic oncology providers in New Jersey.

See all gynecologic oncology providers in New Jersey

Medicare billing

Part B allowed, 2024
$51,983
Medicare patients
98
Services billed
367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →